UNANIMOUS ABOUT PRIORITY

Association Representatives Say PAMA is #1 Concern for Lab Industry

In the kick-off event of G2 Intelligence's 2017 Laboratory Institute (Washington D.C.; Oct. 25-27), representatives of the biggest laboratory-related associations shared their top priorities, which … [Read more...]

PAMA

Draft 2018 CLFS Reveals Fundamental Flaws in PAMA Reporting Exercise; Time to Take Action

By Lâle White  bio As XIFIN predicted, the PAMA reporting exercise has resulted in significant proposed laboratory fee cuts. In fact, the multi-year decrease for the top 20 laboratory tests … [Read more...]

Defense Dept. Extends Lab-Developed Test Demonstration for TRICARE

The Department of Defense announced June 20 that it approved a threeyear extension of the Defense Health Agency Evaluation of Non-United States Food and Drug Administration (FDA) Approved Laboratory … [Read more...]

HEALTH CARE REFORM

Could the AHCA Slow Interest in Genetic Testing?

While it remains uncertain what the Senate will do with the American Health Care Act (AHCA), alarm is spreading about the legislation's implications for the estimated quarter of Americans under the … [Read more...]

REIMBURSEMENT

Molecular Testing Avoids Significant Pay Cuts in 2017 CLFS

The Revamped G Codes for Definitive Drug Testing (underlined text represents changes from 2016 descriptor) The 2017 CLFS includes modified descriptors of the G codes for differential drug tests so … [Read more...]

Foundation Medicine’s Reimbursement Woes May Signal Broader Industry Challenge

Foundation Medicine (Cambridge, Mass.) candidly reported in quarterly financial filings that reimbursement challenges are stymieing the company's growth. The company's lack of Medicare coverage … [Read more...]

Labs Need to Focus on Providing Data-Driven Value for the System, Lab Institute Experts Say

Laboratory leaders are well aware of the unprecedented number of evolutionary forces exerting pressure on the industry and are heavily focused on regulatory and reimbursement uncertainties. But, … [Read more...]

Shift to Gene Panels to Assess Hereditary Cancer Risk Forges Ahead; Evidence of Clinical Utility, Cost-Effectiveness Emerges

A virtually unlimited number of genes tied to hereditary cancer risk can be simultaneously assessed in commercially available tests given both advances in technology and the Supreme Court’s two-year … [Read more...]

Payment Reform Efforts to Support Cancer Care Coordination, Treatment Planning

The American Society of Clinical Oncology (ASCO) is proposing to profoundly reform payment for cancer care. ASCO's Patient-Centered Oncology Payment: Payment Reform to Support Higher Quality, More … [Read more...]

Labs Look to Lean Engineering to Transform Operations

With reimbursement challenging revenue in already constrained budgets, laboratories are increasingly looking for financial stability through cost savings achieved with added operational efficiencies. … [Read more...]


(-0000g2)